Screener
Arcutis Biotherapeutics, Inc. ARQT Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Arcutis Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: Arcutis Biotherapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:21 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001787306-26-000051
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Payment of debt prepayment penalty | (1,000) | — |
| Net cash provided by financing activities | 3,057 | 1,775 |
| Effect of exchange rate changes on cash | (165) | 204 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | (8,786) | 1,096 |
| Cash, cash equivalents, and restricted cash at beginning of period | 43,215 | 71,952 |
| Cash, cash equivalents, and restricted cash at end of period | $34,429 | $73,048 |
| SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: | ||
| Interest expense paid in cash | $6,830 | $5,164 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Arcutis Biotherapeutics, Inc.'s net change in cash?
- Arcutis Biotherapeutics, Inc. (ARQT) reported net change in cash of -$641K in Q2 2026.
- How has Arcutis Biotherapeutics, Inc.'s net change in cash changed year-over-year?
- Arcutis Biotherapeutics, Inc.'s net change in cash decreased by 103.3% year-over-year, from $19.33M to -$641K.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about Arcutis Biotherapeutics, Inc.'s net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude